Immunomedics Inc.
300 American Road
Morris Plains,
NJ 07950
United States - Map
Phone: 973-605-8200
Fax: 973-605-8282
Web Site: http://www.immunomedics.com
| Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkins lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkins lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkins lymphoma. The companys preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, LeukoScan, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. David M. Goldenberg , 71
Founder, Chairman, Chief Scientific Officer, Chief Medical Officer of IBC Pharmaceuticals Inc |
$
700.00K |
$
381.00K | Ms. Cynthia L. Sullivan , 53
Chief Exec. Officer, Pres, Director and Acting Pres of IBC Pharmaceuticals Inc |
$
692.00K |
$
38.00K | Mr. Gerard G. Gorman , 58
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Bus. Devel. & Fin. and Treasurer of IBC Pharmaceuticals Inc |
$
416.00K |
$
0 | Ms. Phyllis Parker ,
Sec. and Sec. of IBC Pharmaceuticals Inc |
N/A
| N/A | Dr. Chau Cheng ,
Associate Director of Investor Relations & Bus. Analysis |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
